MLICM
ACRS icon

Metropolitan Life Insurance Company (MetLife)’s Aclaris Therapeutics ACRS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,901
Closed -$26.7K – 2344
2023
Q3 		$26.7K Buy
3,901
+345
+10% +$2.95K ﹤0.01% 1750
2023
Q2 		$36.9K Buy
3,556
+722
+25% +$6.53K ﹤0.01% 1608
2023
Q1 		$22.9K Sell
2,834
-1,540
-35% -$19.5K ﹤0.01% 1816
2022
Q4 		$68.9K Buy
4,374
+745
+21% +$12K ﹤0.01% 1279
2022
Q3 		$57.1K Hold
3,629
– – ﹤0.01% 1368
2022
Q2 		$50.7K Buy
3,629
+633
+21% +$8.87K ﹤0.01% 1499
2022
Q1 		$51.7K Sell
2,996
-9,700
-76% -$132K ﹤0.01% 1571
2021
Q4 		$185K Hold
12,696
– – ﹤0.01% 2083
2021
Q3 		$229K Hold
12,696
– – ﹤0.01% 1972
2021
Q2 		$223K Buy
+12,696
New +$288K ﹤0.01% 2066
2019
Q1 		– Sell
-12,078
Closed -$89.3K – 2550
2018
Q4 		$89.3K Buy
12,078
+1,022
+9% +$10.5K ﹤0.01% 2337
2018
Q3 		$161K Hold
11,056
– – ﹤0.01% 2156
2018
Q2 		$221K Buy
11,056
+3,589
+48% +$66.3K ﹤0.01% 1885
2018
Q1 		$131K Hold
7,467
– – ﹤0.01% 2154
2017
Q4 		$184K Sell
7,467
-6,907
-48% -$168K ﹤0.01% 1960
2017
Q3 		$371K Hold
14,374
– – ﹤0.01% 1881
2017
Q2 		$390K Buy
14,374
+6,313
+78% +$172K ﹤0.01% 1879
2017
Q1 		$240K Hold
8,061
– – ﹤0.01% 2153
2016
Q4 		$219K Hold
8,061
– – ﹤0.01% 2301
2016
Q3 		$206K Buy
+8,061
New +$171K ﹤0.01% 2319

Other funds holding ACRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ACRS Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 3,901 shares — an estimated $26.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ACRS in Q3 2016 and held it in 20 quarters. The position peaked at $390K in Q2 2017. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,901 Aclaris Therapeutics shares in Q4 2023, an estimated $26.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Aclaris Therapeutics position peaked at $390K in Q2 2017.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.